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Setting up the individual capacity for managing 
genotoxic damage
An unjust peace is better than a just war.
Marcus tullius cicero (106 Bc – 43 Bc)
DnA is an extraordinary molecule. A well-beaten cliché, 
of course, but, at the same time, a succinct summary of the 
complicated and often paradoxical history of the discoveries 
about the various properties of DnA during the course of the 
past century. After it has been demonstrated that the presence 
of DnA in the living cells amounts to much more than a mere 
support or ballast function, it has been proposed that DnA has 
been selected as the ultimate carrier of genetic information in 
the course of evolution because of its stability and resistance 
to alterations. later it became clear, however, that proneness 
to modification is an innate property of DNA-mediated 
inheritance and functions as a major drive of evolution. 
Repair of DnA, therefore, became a focus of research only 
in the last couple of decades, and, as it has always been in 
the history of DnA research, there were numerous turning 
points. For instance, genes and proteins participating in DnA 
repair in humans were discovered in the course of studying 
the associated human conditions (16), and it was proposed, 
respectively, that defects in the coding regions of most of the 
essential DnA repair genes would lead almost invariably to 
severe, early-onset disease. examples to support this notion 
were numerous, and the case report of Fujiwara et al. in 1981 
(23) and the follow-up reports by itoh et al. in 1996 (33) and 
horibata et al. in 2004 (30) that homozygous carriership of 
null alleles of the ERCC6 (CSB) gene may only result in 
photosensitivity instead of full-blown cockayne syndrome 
were hotly disputed, checked and rechecked by sequencing 
studies. this resulted in the emergence of the novel term “UV-
sensitivity syndromes” and the realization that allelic disorders 
of DnA repair may belong to the extremes of the clinical 
spectrum, some presenting with very severe phenotype, 
other subclinical or virtually latent except in the presence of 
specific triggers. The breaking point in the views about the 
‘permissible’ degree of variation in DnA repair genes was, 
however, in 1990, when Ara et al. (3) reported that the pro72-
to-arg (P72R) change in exon 4 of the gene coding for the 
tumour-suppressor protein p53 is a polymorphism rather than 
a mutation. in mid-90-ties, numerous polymorphisms in basic 
DnA repair genes (XPD, ERCC1, XRCC1, XRCC3, etc.) were 
identified (7, 65). Several of these have been found later to be 
associated with diminished capacity for repair of DnA damage 
and, respectively, with increased risk of various cancers and 
possibly with other age-related diseases (44, 51, 60, 67). in 
2000, the polymorphic insertion of 83 bp in intron 9 of the 
XPC gene was reported (36). ever since, the effects of DnA 
polymorphisms on proficiency of DNA repair and, respectively, 
on the closely related matter of individual repair capacity has 
been explored under physiological conditions and in disease. 
it has been found that the capacity to repair DnA damage 
may vary significantly between individuals coming out as 
healthy on routine physical and laboratory examinations. this 
variance in itself does not generally cause distress or disease, 
unless under specific conditions or specific type of genotoxic 
stress (e.g. increased propensity to sunburn in individuals with 
specific genotypes) (27, 48) but, taken together with other 
factors, may increase the risk for certain types of cancer (e.g. 
increased risk of lung or colon cancer in smokers or increased 
risk of melanoma in light-skinned individuals with a history 
of extensive sun exposure). on the other hand, carriership 
of polymorphisms in genes coding for proteins involved in 
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ABSTRACT
Capacity to repair DNA damage may vary significantly between individuals coming out as healthy on routine physical and 
laboratory examinations. This variance does not generally cause distress or disease unless in case that specific triggers are 
present, but, taken together with other factors, may increase the risk for certain types of cancer or may modulate the outcome 
of anticancer therapies. Carriership of certain polymorphic variants in DNA repair genes may also modify the course of the 
normal process of aging. The present paper reviews the role of some of the common polymorphisms in DNA repair genes and in 
genes involved in the maintenance of genomic integrity; and their association, separately or in combination, with the ‘healthy’ 
phenotype and with certain diseases and conditions related to exposure to increased levels of oxidative damage. 
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DnA repair was found to modulate the outcome of anticancer 
therapies in terms of survival and therapy-related toxicity 
(26, 66), as most anticancer therapies are based on inflicting 
genotoxic damage on cancer cells so as to reduce their 
proliferative capacity and/or induce apoptosis. What is more, 
it has been shown that carriership of polymorphic variants in 
DNA repair genes may influence the process of aging. Very 
recently, it has been reported that murine models defective 
by the nucleotide excision repair genes Ercc1 and Xpd may 
exhibit accelerated senescence of the wall of the blood vessels, 
with resulting vascular stiffness and arterial hypertension at a 
young age (19). 
information on the role of the non-disease polymorphic 
variants of genes associated with repair of DnA damage 
and management of genome integrity has been steadily 
accumulating for the past 20 years. the present paper reviews 
the role of some of the common polymorphisms in DnA repair 
genes and in genes involved in the maintenance of genomic 
integrity and their association, separately or in combination, 
with certain diseases and conditions related to exposure to 
increased levels of oxidative damage. 
Polymorphisms in genes encoding products 
directly responsible for DNA repair and/or 
induction of apoptosis 
One may know how to gain a victory, and know not how to 
use it.
Pedro calderon de la Barca (1600–1681)
Of the numerous genetic polymorphisms that may influence the 
individual capacity for repair of DnA damage, few are those 
which are endowed with an information value of their own. 
Among the latter prominent are the already mentioned P72R 
polymorphism in the TP53 gene and several single-nucleotide 
substitutions in the gene coding for the helicase XPD. their 
applicability may vary, however, depending on whether they 
are used alone or in combination with other factors, or the 
context in which they are being used. 
p53
the responsibility for integrating the signals for presence of 
genotoxic damage, for quantification of the amount of damage, 
and taking the decision about the fate of the damaged cell is 
essentially a prerogative of p53. Germline mutations affecting 
regions of the gene encoding domains responsible for the 
properties of p53 to transactivate its target genes or its retention 
in the nucleus usually result in li-Fraumeni syndrome, a 
cancer-prone phenotype (53). Several polymorphisms in the 
coding sequence as well as in the introns of the tP53 gene 
have been identified so far (62). 
After assessment of the amount and the scale of DnA 
damage, p53 may launch one of two basic pathways, one of 
which is ‘repair mode’, that is, G1/S cell cycle arrest until 
DnA damage is repaired; or, alternatively, the programmed 
cell death routine may be activated. in both cases, cells which 
have sustained genotoxic DnA damage (or almost any type 
of damage, for that matter) are specifically dealt with in order 
to effectively decrease the amount of damage. the means to 
achieve this, and, respectively, the outcomes may be very 
different – the damaged DnA may be repaired and the cell 
may live (and, potentially, divide further) – admittedly with 
some risk that unrepaired or improperly repaired damage 
might persist further; or the cell may die by apoptosis (and 
be promptly replaced by a new cell produced by the stem cell 
population). Assessment of damage and launching one type of 
response or another is largely dependent on p53, therefore, it 
is a prime target for inactivation in cancer cells. Alterations 
in the gene coding for p53 (loss of allelic copies, inactivating 
mutations, promoter methylation, etc.) are common in tumours 
and loss of activity of p53 may be one of the last barriers 
that a cell already on the way of cancerous transformation 
must overcome before becoming truly malignant (45, 50). 
Restoration of p53 function and/or increasing the levels of 
normal isoforms of p53 in cancer cells is one of the therapeutic 
options in modern anticancer therapy (39, 47). it has been 
shown in murine models, however, that constitutively high 
levels of the non-cancerous isoforms of p53 are associated with 
a striking phenotype of premature aging (24). it is believed that 
the aging is a major anticancer mechanism that p53 deploys in 
order to ensure that cells at high risk of significant alterations 
in their DnA are systematically and safely removed from the 
replicative pool (10, 35, 57). 
Apparently, the levels of p53 as well as its activity must be 
exquisitely balanced in order for a healthy individual to age at 
a normal rate and to remain healthy throughout. the properties 
of ‘normal’ p53 in regard to its ability to induce cell cycle arrest 
or apoptosis may not be equivalent. Whether p53 is a stronger 
transcription activator or a stronger inducer of apoptosis 
depends on the genotype for the P72R polymorphism in exon 4, 
with the R allele conferring pro-apoptotic properties and the P 
allele more strongly associated with the ability to induce G1/S 
cell cycle arrest (69). in young and healthy individuals, the 
presence of the one or the other genotype does not constitute 
either advantage or disadvantage, except that individuals with 
the PP genotype may have a slight reproductive disadvantage 
compared to RR and PR individuals because of a somewhat 
higher incidence of early embryo implantation failures (20). 
the P allele is more common in the geographical areas near the 
equator while the R allele generally becomes more common 
nearer the poles (64), which is believed by some authors to 
be related to the dose of environmental genotoxic agents 
(specifically, UV radiation) regularly received at different 
latitudes and the presence of other protective factors (14). 
carriership of the different allelic forms of p53, especially 
homozygous carriership, however, may play a role of its 
own in older individuals and/or individuals affected with 
different conditions. this role may be complex, as, on the 
one hand, homozygous carriership of the pro-apototic R 
allele has been shown to decrease the incidence of cancer in 
elderly individuals almost twofold (17), while carriership of 
homozygous P allele has been shown to be associated with an 
increase in median lifespan compared to RR homozygotes (6). 
longevity associated with carriership of different allelic forms 
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of p53 seems to have its specific cellular substrates, as it has 
already been shown that reduced p53 activity in genetically 
engineered mice is associated with higher counts of circulating 
hematopoietic progenitor cells in advanced age compared to 
normal control mice (5, 18). it has been demonstrated, however, 
that individuals with homozygous R/R genotypes may have 
poorer outcomes after incidents of acute ischaemia, which is 
most likely related to the proneness of damaged R/R cells to 
apoptosis compared to cells with P/R and P/P genotypes (1, 
25). Apparently, the process of physiological aging as well as 
the process of development of disease may serve as tipping 
points in the balance between the pro-transactivation and the 
pro-apoptotic properties of p53, with consequences dependent 
on the combined impact of other factors (35, 72). 
XPD
XPD is AtP-dependent 5’–3’ DnA helicase, component of 
the TFIIH basal transcription factor (68). Since the function of 
XPD is indispensable in both basic types of repair by nucleotide 
excision, mutations in the XPD gene may produce any of 
the basic NER-deficient phenotypes in humans – xeroderma 
pigmentosum (XP); XP combined with cockayne syndrome; 
and trichothiodystrophy, depending on the site and the type 
of the mutation (38). Several polymorphic single-nucleotide 
substitutions in the XPD gene have been identified in exons 6, 
8, 10, 17, 22, and 23 (7, 65). two of these polymorphisms – 
Asp312Asn (exon 10) and lys751Gln (exon 23), are considered 
common in all populations. carriership of any of these 
generally results in higher levels of DnA adducts, suggesting 
lower capacity for repair of DnA lesions via neR (31, 41). 
human lymphoblastoid cells carrying the Asn allelic variant 
have been reported to exhibit diminished apoptotic response 
to genotoxic challenge (63). increased risk for various cancers 
and for development of senile cataract has been found to be 
associated with carriership of the Asp312Asn and lys751Gln 
polymorphisms (44, 51, 67, 71). Also, carriership status of 
the one or the other allele may play a role in the outcome of 
different anticancer therapies (see below). 
Role of mutations in genes not related directly 
to DNA repair but associated with maintenance 
of genome integrity in the constitution of 
pathological phenotypes 
You cannot simultaneously prevent and prepare for war.
Albert einstein (1879–1955)
the idea of individual repair capacity as the product of genetic 
background (carriership of polymorphic alleles of genes involved 
in DnA repair which is associated with increased or decreased 
ability for efficient and/or timely repair of everyday DNA 
damage) and environmental factors (new sources of genotoxic 
damage or increase in the level of preexisting genotoxic damage) 
covers and explains most of the known cancer predispositions. 
it has been repeatedly demonstrated, however, that oxidative 
damage to cells and tissues is a major pathogenetic mechanism 
in many seemingly unrelated (that is, non-cancerous) conditions 
such as insulin resistance, atherosclerosis, Parkinson’s and 
Alzheimer’s disease, and possibly others. All these diseases and 
conditions have a common unifying point though, as they are 
characterized by a propensity for accelerated aging of certain 
types of cells and tissues. Also, these diseases and conditions are 
considered to be diseases typical of advanced age, despite the 
fact that modern humans live up to several decades longer than 
men of 150 years ago and therefore the concept of advanced age 
apparently is up for revision. indeed, the incidence of cancer 
is much higher in the group of 65 years and above than in any 
other age group, but prolonged and/or intensive oxidative stress 
may not manifest as cancer proneness only. increased levels of 
oxidative stress are presently considered to be a characteristic 
feature of insulin-resistant diabetes and atherosclerosis (4, 22), 
and it has been found in animal models as well as in humans that 
predispositions to insulin-resistant phenotype may result from 
heritable variations in genes coding for products participating 
in certain types of DNA repair (specifically, the Fpg/Nei family 
of glycosylases which perform the first steps of BER repair of 
oxidized bases in DnA (58, 73)) and also from mutations in 
genes associated with the maintenance of the genome integrity, 
but not strictly related to DnA repair, such as HMGA1 (15, 21). 
hMGA proteins play a role in the maintenance of the architecture 
and the dynamics of the chromatin and, respectively, in the 
regulation of transcription of various genes in non-cancerous and 
cancer cells (2, 43). it has been proposed that homozygocity for 
certain hMGA1 mutations may result in decreased intrauterine 
viability in mammal embryos, while carriership of only one 
mutant allele of hMGA1 may be associated with predisposition 
for development of insulin resistance (15, 21). Recent theories 
have put forth faulty DnA repair as a major mechanism in the 
pathogenesis of the insulin resistant phenotypes (metabolic 
syndrome, diabetes type 2) and atherosclerosis (42, 46) and it 
has been proposed that insulin resistance is, in fact, a low-grade 
premalignant state in which DnA damage is slowly accumulating 
to a point where it cannot be handled by the repair machinery of 
the cell, triggering accelerated aging and/or carcinogenesis (54). 
it has been demonstrated that the risk for development of 
insulin resistance may be modulated by carriership of certain 
genetic polymorphisms in genes coding for products involved 
in the repair of DnA damage, among which prominent is the 
already mentioned P72R polymorphism in the TP53 gene. it 
has been found that carriership of the pro-apoptotic (R) allele 
of p53 is associated with higher risk of development of diabetes 
type 2 than in non-carriers (8, 55). Mass apoptosis of selected 
cell populations is a hallmark of the pathogenesis of some of the 
common severe consequences of uncontrolled hyperglycemia 
– accelerated vascular aging, retinopathy, neuropathy, etc. it 
could be hypothesized that the presence of the pro-apoptotic 
form of p53 in cells which are already under increased levels 
of genotoxic stress for any reason, may serve well when the 
organism is young, but not that well as the organism ages, 
possibly as an expression of the phenomenon of antagonistic 
pleiotropy (35). More specifically, in case that the underlying 
hyperglycemic state is poorly managed, the pro-apoptotic 
p53 may handle the ongoing avalanche of genotoxic damage 
at young age by routing cells with potential for oncogenic 
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transformation to the programmed cell death pathway. As the 
remaining reserve of stem cells in the tissues of the young adult 
is fully functional, it promptly produces new cells to replace 
these that have been removed by apoptosis. once the stem 
cell reserve is depleted, however, or its replicative capacity 
is diminished, as happens as age advances, permanent tissue 
damage settles in. thus, the background of increased levels 
of oxidative stress is provided by the preexisting hMGA1 
mutation while carriership of other modulating factors may 
play a role in the formation of the risk for development of late 
vascular and possibly retinal pathology associated with insulin 
resistant phenotypes. the situation may be somewhat different 
with neurological damage due to oxidative stress, as the 
possibility for replacement of differentiated neural cells in the 
adult organism is, at best, limited. it has been demonstrated, 
however, that some terminally differentiated (and, therefore, 
non-dividing) cell types, including neurons tend to suppress 
global genome repair in order to focus all repair machinery 
to repair actively transcribed genes (12, 32, 49), therefore 
it might be the case that checks for genotoxic damage (and, 
consequently, removal of cells with genomic damage deemed 
to be serious enough to trigger apoptosis) are less frequent in 
neural cells, even when they are in conditions of increased 
levels of genotoxic damage. 
Using information about individual repair 
capacity for design of personalized anticancer 
therapies
The best weapon against an enemy is another enemy.
Friedrich nietzsche (1844–1900) 
Modern anticancer strategies involve selection of therapeutic 
strategies based on the individual characteristics of the 
patient and design of a personalized therapeutic regimen. 
Personalization as we know it usually takes into account 
the type and the basic characteristics of the cancer and then 
matches the possible therapeutic options to the particular 
patient in order to determine whether one therapeutic regimen 
could be more successful and free of adverse reactions than 
another. A mainstream branch of both classic and modern 
anticancer therapy is based on genotoxic treatment – that is, 
introduction of enough genotoxic damage into cancer cells so 
as to reroute them to the programmed cell death pathway (if 
it has not been disabled already) or delaying their growth by 
induction of cell cycle arrest. the amount of genotoxic damage 
associated with therapy is usually enough to produce adverse 
effects in healthy tissues. the question is, is a cell with inherent 
low-than-average capacity for DnA repair (for example, 
because of carriership of certain genetic polymorphisms) at 
advantage or at disadvantage when it comes to carcinogenesis 
and success of anticancer treatments? the answer is complex, 
to say at least. Accumulation of unrepaired DnA damage in 
a cell with innate capacity for repair somewhat lower than 
what is considered normal (for the cell type, for the age group, 
for the species, etc.) may cause premature senescence of the 
cell and/or its elimination via the apoptosis pathway; or may 
trigger neoplastic transformation. once cancer has settled in, 
however, and anticancer therapy has been started, it is likely 
that cancer cells with normal capacity for repair of DnA 
damage would repair the lesions induced by the genotoxic 
agents of chemo-and radiotherapy more effectively than cells 
with lower capacity for repair. in practical terms, this translates 
to lower risk for treatment failures and for development of 
resistance to various anticancer agents in cancer cells with low 
repair capacity. it has already been shown for different types 
of tumours (hematological as well as solid) that carriership of 
allelic forms of DnA polymorphisms associated with lower 
capacity for DNA repair (specifically XPD polymorphisms in 
exon 10 and exon 23, as well as polymorphisms in several genes 
participating in repair by BeR and recombination) may predict 
higher rates of response to treatment and better outcomes in 
terms of progression-free survival (37, 40, 56). interestingly, 
there are exceptions to this, as it has been shown that the 
presence of the Gln allele of the lys751Gln polymorphism of 
the XPD gene may actually be associated with reduced survival 
in patients treated with combined platinum/5-fluorouracil 
regimens for advanced colorectal cancer (52). 
lower capacity for repair of therapy-associated genotoxic 
damage may also mean that collateral genotoxic damage to 
healthy tissues following anticancer therapy may be more 
extensive and may be repaired less effectively. carriership 
of polymorphisms in the XPD, ERCC1 and XRCC1 genes 
conferring lower capacity for DnA repair has been shown 
to be associated with higher risk for acute and late toxicity 
in ‘standard’ chemotherapy or radiotherapy regimens (40, 
59). What is more, polymorphic variants of genes which are 
not known to be associated with substantial decrease in the 
capacity for DnA repair may apparently also modify the risk 
for toxicity following anticancer therapy, as the R allele of 
the P72R polymorphism has been found to be more frequent 
in vascular skin lesions following radiotherapy for breast 
cancer than the P allele (61). With the variety of compounds 
with antitumour properties constantly increasing, it could be 
expected that the predictive value of polymorphisms in genes 
related to DnA repair and maintenance of genome integrity 
will become an even more important factor in personalization 
of anticancer therapies. 
Usefulness of predictive testing for 
polymorphisms in DNA repair genes – possible 
ethical considerations 
What’s the use of worrying? It’s never been worthwhile...
Pack Up Your Troubles in Your Old Kit-Bag, World War I 
marching song (1915)
Predictive testing for conditions with genetic bases has always 
been a hotspot of dispute and decisions for undertaking any 
genetic testing procedures are generally considered to be 
strictly a matter of personal choice. When it comes to testing for 
multiple conditions which are, by any definition, very common 
and may (or may not) have severe, lifelong consequences, taking 
the burden of responsibility of knowing that one may develop 
one condition or another and especially that one may pass it to 
its offspring becomes much more than a matter of individual 
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preference. Since cancer, insulin resistance, atherosclerosis, 
etc. are, by general convention, multifactorial diseases, it is 
important that prior to any predictive testing the individual is 
aware that the ensuing genetic findings are not the sole cause 
for any condition or disease they may develop in the future. 
this may bring about several serious issues, mainly related to 
difficulties in evaluation of the biological and statistical sense 
of the test result. For example, a proven homozygous carrier of 
the P allele of p53 alleles may learn and understand that this is 
associated with an increase in the risk of cancer in comparison to 
the R allele carries, but they might not be able to evaluate overall 
cancer prevalence estimates by age group and the proportion 
of R allele carriers in the particular population so as to know 
whether this increase in the risk is significant or not. Similarly, 
carriership of the XPD exon 10 or exon 23 polymorphisms or 
the XPc 83 bp insertion polymorphism in the homozygous 
state may increase the baseline risk for several types of cancer 
(for example, lung and skin cancer), but in individuals who 
are recreationally or professionally exposed to environmental 
risk factors (smoke/fumes and UV, respectively), this increase 
could be expected to be much larger, and it would be virtually 
impossible to distinguish the risk conferred by the carriership of 
the genetic factor alone and the risk related to the environmental 
hazard in the particular individual. therefore, instead of testing 
for separate factors with genetic bases whose importance 
may be difficult to evaluate, one may instead prefer general 
assessment of global repair capacity in primary cell cultures 
(11, 13, 34, 39) which would produce an overall estimate of 
the capacity for repair as a function of the genotype/phenotype 
interaction combined with testing for phenotypic markers of 
the rate of cellular aging, such as rate of attrition of telomere 
length measured in peripheral leucocytes (28, 29). Still, as this 
carries some predictive value, one may decline any type of 
direct testing and choose lifestyle modifications such as quitting 
smoking, use of pre-irradiation and post-irradiation anti-UV 
measures (9, 70), etc. Knowledge about carriership of specific 
allelic forms, however, may prove very useful in individuals 
in which certain conditions have already occurred, such as in 
individuals with insulin resistance already settled in, patients 
with known vascular pathology, and patients eligible for certain 
types of therapy in which the outcome may be modified by 
variance in the capacity for DnA repair (genotoxic therapy for 
various cancers). 
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